The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis

K Kamenov, C Twomey, M Cabello, A M Prina, J L Ayuso-Mateos, K Kamenov, C Twomey, M Cabello, A M Prina, J L Ayuso-Mateos

Abstract

Background: There is growing recognition of the importance of both functioning and quality of life (QoL) outcomes in the treatment of depressive disorders, but the meta-analytic evidence is scarce. The objective of this meta-analysis of randomized controlled trials (RCTs) was to determine the absolute and relative effects of psychotherapy, pharmacotherapy and their combination on functioning and QoL in patients with depression.

Method: One hundred and fifty-three outcome trials involving 29 879 participants with depressive disorders were identified through database searches in Pubmed, PsycINFO and the Cochrane Central Register of Controlled Trials.

Results: Compared to control conditions, psychotherapy and pharmacotherapy yielded small to moderate effect sizes for functioning and QoL, ranging from g = 0.31 to g = 0.43. When compared directly, initial analysis yielded no evidence that one of them was superior. After adjusting for publication bias, psychotherapy was more efficacious than pharmacotherapy (g = 0.21) for QoL. The combination of psychotherapy and medication performed significantly better for both outcomes compared to each treatment alone yielding small effect sizes (g = 0.32 to g = 0.39). Both interventions improved depression symptom severity more than functioning and QoL.

Conclusion: Despite the small number of comparative trials for some of the analyses, this study reveals that combined treatment is superior, but psychotherapy and pharmacotherapy alone are also efficacious for improving functioning and QoL. The overall relatively modest effects suggest that future tailoring of therapies could be warranted to better meet the needs of individuals with functioning and QoL problems.

Keywords: Depression; functioning; meta-analysis; pharmacotherapy; psychotherapy; quality of life.

Figures

Fig. 1.
Fig. 1.
Flow chart of study selection.
Fig. 2.
Fig. 2.
Total standardized effect sizes (Hedges' g) of psychotherapy and pharmacotherapy against control condition for functioning and QoL.
Fig. 3.
Fig. 3.
Standardized effect sizes (Hedges' g) of psychotherapy against pharmacotherapy on functioning and QoL.
Fig. 4.
Fig. 4.
Standardized effect sizes (Hedges' g) of combined treatment against psychotherapy and medication alone on functioning and QoL.

References

    1. APA (1980). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. American Psychiatric Association: Washington, DC.
    1. APA (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, Revised (DSM-III-TR). American Psychiatric Association: Washington, DC.
    1. APA (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (DSM-IV-TR). American Psychiatric Association: Washington, DC.
    1. Bosmans JE, van Schaik DJ, de Bruijne MC, van Hout HP, van Marwijk HW, van Tulder MW, Stalman WA (2008). Are psychological treatments for depression in primary care cost-effective? Journal of Mental Health Policy and Economics 11, 3–15.
    1. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Erlbaum: Hillsdale, NJ.
    1. Cohen RM, Greenberg JM, IsHak WW (2013). Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD. JAMA Psychiatry 70, 343–350.
    1. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL (1993). The enduring psychosocial consequences of mania and depression. American Journal of Psychiatry 150, 720–727.
    1. Cuijpers P, Andersson G, Donker T, van Straten A (2011). Psychological treatment of depression: results of a series of meta-analyses. Nordic Journal of Psychiatry 65, 354–364.
    1. Cuijpers P, Karyotaki E, Andersson G, Li J, Mergl R, Hegerl U (2015). The effects of blinding on the outcomes of psychotherapy and pharmacotherapy for adult depression: a meta-analysis. European Psychiatry 30, 685–693.
    1. Cuijpers P, Li J, Hofmann SG, Andersson G (2010). Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis. Clinical Psychology Review 30, 768–778.
    1. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF III (2013). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry 12, 137–148.
    1. Cuijpers P, van Straten A, Andersson G, van Oppen P (2008a). Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. Journal of Consulting and Clinical Psychology 76, 909–922.
    1. Cuijpers P, Van Straten A, Warmerdam L, Smits N (2008b). Characteristics of effective psychological treatments of depression: a metaregression analysis. Psychotherapy Research 18, 225–236.
    1. Deeks J, Higgins J, Altman D (2008). Analysing data and undertaking meta-analyses In Cochrane Handbook for Systematic Reviews of Interventions (ed. Higgins J. P. T. and Green S.), pp. 243–296. Wiley-Blackwell: Chichester, UK.
    1. De Silva MJ, Cooper S, Li HL, Lund C, Patel V (2013). Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis. British Journal of Psychiatry 202, 253–260.
    1. Duval S, Tweedie R (2000). Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455–463.
    1. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin 29, 321–326.
    1. Gaudiano BA, Herbert JD (2005). Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychotherapy and Psychosomatics 74, 17–25.
    1. Gemmill MC, Thomson S, Mossialos E (2008). What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. International Journal for Equity in Health 7, 12.
    1. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23, 56–62.
    1. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal 343, d5928.
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. British Medical Journal 327, 557–560.
    1. IsHak W, Burt T, Sederer L (2002). Outcome Measurement in Psychiatry: a Critical Review. American Psychiatric Publishing: Washington, DC.
    1. IsHak WW, Greenberg JM, Balayan K, Kapitanski N, Jeffrey J, Fathy H, Fakhry H, Rapaport MH (2011a). Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harvard Review of Psychiatry 19, 229–239.
    1. IsHak WW, Ha K, Kapitanski N, Bagot K, Fathy H, Swanson B, Vilhauer J, Balayan K, Bolotaulo NI, Rapaport MH (2011b). The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harvard Review of Psychiatry 19, 277–289.
    1. Kamenov K, Cabello M, Coenen M, Ayuso-Mateos JL (2015). How much do we know about the functional effectiveness of interventions for depression? A systematic review. Journal of Affective Disorders 188, 89–96.
    1. Kelly K, Posternak M, Alpert JE (2008). Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues in Clinical Neuroscience 10, 409–418.
    1. Lam RW, Parikh SV, Michalak EE, Dewa CS, Kennedy SH (2015). Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Annals of Clinical Psychiatry 27, 142–149.
    1. Layard R, Clark DM, Knapp M, Mayraz G (2007). Cost-benefit analysis of psychological therapy. National Institute Economic Review 202, 90–98.
    1. Madden RH, Glozier N, Fortune N, Dyson M, Gilroy J, Bundy A, Llewellyn G, Salvador-Carulla L, Lukersmith S, Mpofu E, Madden R (2015). In search of an integrative measure of functioning. International Journal of Environmental Research and Public Health 12, 5815–5832.
    1. Marcus SC, Olfson M (2010). National trends in the treatment for depression from 1998 to 2007. Archives of General Psychiatry 67, 1265–1273.
    1. McAllister-Williams RH (2006). NICE guidelines for the management of depression. British Journal of Hospital Medicine 67, 60–61.
    1. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. Journal of Clinical Psychiatry 74, 595–602.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International Journal of Surgery 8, 336–341.
    1. Norcross JC (1990). An eclectic definition of psychotherapy In What is Psychotherapy? Contemporary Perspectives (ed. Zeig J. K. and Munion W. M.), pp. 218–220. Jossey-Bass: San Francisco, CA.
    1. Renner F, Cuijpers P, Huibers MJ (2014). The effect of psychotherapy for depression on improvements in social functioning: a meta-analysis. Psychological Medicine 44, 2913–2926.
    1. Riley RD, Higgins JP, Deeks JJ (2011). Interpretation of random effects meta-analyses. British Medical Journal 342, d549.
    1. Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, Kikuchi T, Ono Y (2009). Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Australian and New Zealand Journal of Psychiatry 43, 539–547.
    1. Senn SJ (2009). Overstating the evidence: double counting in meta-analysis and related problems. BMC Medical Research Methodology 9, 10.
    1. Sheehan D (1983). The Anxiety Disease. Scribner's: New York.
    1. Sibbald B, Roland M (1998). Understanding controlled trials. Why are randomised controlled trials important? British Medical Journal 316, 201.
    1. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Medicine 10, e1001403.
    1. Spielmans GI, Berman MI, Usitalo AN (2011). Psychotherapy versus second-generation antidepressants in the treatment of depression: a meta-analysis. Journal of Nervous and Mental Disease 199, 142–149.
    1. Spring B (2007). Evidence-based practice in clinical psychology: what it is, why it matters; what you need to know. Journal of Clinical Psychology 63, 611–631.
    1. Trompenaars FJ, Masthoff ED, Van Heck GL, Hodiamont PP, De Vries J (2006). Relationship between mood related disorders and quality of life in a population of Dutch adult psychiatric outpatients. Depression and Anxiety 23, 353–363.
    1. Vittengl JR, Clark LA, Jarrett RB (2009). Deterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depression. Journal of Affective Disorders 112, 135–143.
    1. von Wolff A, Holzel LP, Westphal A, Harter M, Kriston L (2012). Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: a systematic review and meta-analysis. BMC Psychiatry 12, 61.
    1. Ware JE Jr., Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 30, 473–483.
    1. Weissman MM, Prusoff BA, Thompson WD, Harding PS, Myers JK (1978). Social adjustment by self-report in a community sample and in psychiatric outpatients. Journal of Nervous and Mental Disease 166, 317–326.
    1. WHO (1992). International Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). World Health Organization: Geneva.
    1. World Health Organization Quality of Life Group (1997). Measuring quality of life ().
    1. Zimmerman M, Martinez JH, Attiullah N, Friedman M, Toba C, Boerescu DA (2014). The remission from depression questionnaire as an outcome measure in the treatment of depression. Depression and Anxiety 31, 533–538.
    1. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D (2006). How should remission from depression be defined? The depressed patient's perspective. American Journal of Psychiatry 163, 148–150.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe